Sentinel Node Biopsy Should Not be Routine in Older Patients with ER-Positive HER2-Negative Breast Cancer Who Are Willing and Able to Take Hormone Therapy.
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
04
02
2021
accepted:
26
02
2021
pubmed:
6
4
2021
medline:
28
9
2021
entrez:
5
4
2021
Statut:
ppublish
Résumé
The SSO Choosing Wisely campaign recommended selective sentinel lymph node biopsy (SLNB) in clinically node-negative women aged ≥ 70 years with ER+ breast cancer. We sought to assess the association of SLNB positivity, adjuvant treatment, and survival in a population-based cohort. Women aged ≥ 70 years treated for ER+ HER2- breast cancer between 2010 and 2016 were identified in our prospective provincial database. Overall survival (OS) and breast cancer-specific survival (BCSS) were assessed using Kaplan-Meier analysis. Multivariable logistic regression was used to assess the association of SLNB positivity with use of adjuvant treatments and survival outcomes. We identified 2662 patients who met study criteria. SLNB was positive in 25%. Increased use of chemotherapy (ChT), hormone therapy (HT), and radiotherapy (RT) was significantly associated with SLNB positivity. Five-year OS was 86%, and BCSS was 96% with median follow-up of 4.3 years. BCSS was worse with grade 3 disease (HR 4.1, 95% CI 2.1-8.1, p < 0.0001) and better with HT (HR 0.5 95% CI 0.3-0.9, p = 0.01). Patients with a positive SLNB treated without adjuvant therapy had lower BCSS (HR 3.2 95% CI 1.2-8.4, p = 0.017) than those with a negative SLNB, but patients with a positive SLNB treated with any combination of ChT, HT, and/or RT, had similar BCSS to those with a negative SLNB. BCSS in this population was excellent at 96%, and BCSS was similar with negative and positive SLNB when patients received HT. SLNB can be omitted in elderly patients willing to take HT.
Sections du résumé
BACKGROUND
BACKGROUND
The SSO Choosing Wisely campaign recommended selective sentinel lymph node biopsy (SLNB) in clinically node-negative women aged ≥ 70 years with ER+ breast cancer. We sought to assess the association of SLNB positivity, adjuvant treatment, and survival in a population-based cohort.
PATIENTS AND METHODS
METHODS
Women aged ≥ 70 years treated for ER+ HER2- breast cancer between 2010 and 2016 were identified in our prospective provincial database. Overall survival (OS) and breast cancer-specific survival (BCSS) were assessed using Kaplan-Meier analysis. Multivariable logistic regression was used to assess the association of SLNB positivity with use of adjuvant treatments and survival outcomes.
RESULTS
RESULTS
We identified 2662 patients who met study criteria. SLNB was positive in 25%. Increased use of chemotherapy (ChT), hormone therapy (HT), and radiotherapy (RT) was significantly associated with SLNB positivity. Five-year OS was 86%, and BCSS was 96% with median follow-up of 4.3 years. BCSS was worse with grade 3 disease (HR 4.1, 95% CI 2.1-8.1, p < 0.0001) and better with HT (HR 0.5 95% CI 0.3-0.9, p = 0.01). Patients with a positive SLNB treated without adjuvant therapy had lower BCSS (HR 3.2 95% CI 1.2-8.4, p = 0.017) than those with a negative SLNB, but patients with a positive SLNB treated with any combination of ChT, HT, and/or RT, had similar BCSS to those with a negative SLNB.
CONCLUSIONS
CONCLUSIONS
BCSS in this population was excellent at 96%, and BCSS was similar with negative and positive SLNB when patients received HT. SLNB can be omitted in elderly patients willing to take HT.
Identifiants
pubmed: 33817760
doi: 10.1245/s10434-021-09839-6
pii: 10.1245/s10434-021-09839-6
doi:
Substances chimiques
Hormones
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5950-5957Informations de copyright
© 2021. Society of Surgical Oncology.
Références
Choosing Wisely. 2016. https://www.choosingwisely.org/clinician-lists/sso-sentinel-node-biopsy-in-node-negative-women-70-and-over/ . Accessed 23 Nov 2020
Martelli G, Boracchi P, De Palo M, et al. A randomized trial comparing axillary dissection to no axillary dissection in older patients with T1N0 breast cancer: results after 5 years of follow-up. Ann Surg. 2005;242(1):1–9. https://doi.org/10.1097/01.sla.0000167759.15670.14 .
doi: 10.1097/01.sla.0000167759.15670.14
pubmed: 15973094
pmcid: 1357697
International Breast Cancer Study Group, Rudenstam CM, Zahrieh D, et al. Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: first results of International Breast Cancer Study Group Trial 10–93. J Clin Oncol. 2006;24(3):337–44. https://doi.org/10.1200/JCO.2005.01.5784 .
doi: 10.1200/JCO.2005.01.5784
Louie RJ, Gaber CE, Strassle PD, Gallagher KK, Downs-Canner SM, Ollila DW. Trends in surgical axillary management in early stage breast cancer in elderly women: continued over-treatment. Ann Surg Oncol. 2020;27(9):3426–33. https://doi.org/10.1245/s10434-020-08388-8 .
doi: 10.1245/s10434-020-08388-8
pubmed: 32215758
pmcid: 7415703
Smith BD, Jiang J, McLaughlin SS, et al. Improvement in breast cancer outcomes over time: are older women missing out? J Clin Oncol. 2011;29(35):4647–53. https://doi.org/10.1200/JCO.2011.35.8408 .
doi: 10.1200/JCO.2011.35.8408
pubmed: 22067407
Yood MU, Owusu C, Buist DS, et al. Mortality impact of less-than-standard therapy in older breast cancer patients. J Am Coll Surg. 2008;206(1):66–75. https://doi.org/10.1016/j.jamcollsurg.2007.07.015 .
doi: 10.1016/j.jamcollsurg.2007.07.015
pubmed: 18155570
Schonberg MA, Marcantonio ER, Li D, Silliman RA, Ngo L, McCarthy EP. Breast cancer among the oldest old: tumor characteristics, treatment choices, and survival. J Clin Oncol. 2010;28(12):2038–45. https://doi.org/10.1200/JCO.2009.25.9796 .
doi: 10.1200/JCO.2009.25.9796
pubmed: 20308658
pmcid: 2860406
Truong PT, Bernstein V, Wai E, Chua B, Speers C, Olivotto IA. Age-related variations in the use of axillary dissection: a survival analysis of 8038 women with T1-ST2 breast cancer. Int J Radiat Oncol Biol Phys. 2002;54(3):794–803. https://doi.org/10.1016/s0360-3016(02)02973-5 .
doi: 10.1016/s0360-3016(02)02973-5
pubmed: 12377331
Welsh JL, Hoskin TL, Day CN, Habermann EB, Goetz MP, Boughey JC. Predicting nodal positivity in women 70 years of age and older with hormone receptor-positive breast cancer to aid incorporation of a society of surgical oncology choosing wisely guideline into clinical practice. Ann Surg Oncol. 2017;24(10):2881–8. https://doi.org/10.1245/s10434-017-5932-1 .
doi: 10.1245/s10434-017-5932-1
pubmed: 28766197
Chagpar AB, Hatzis C, Pusztai L, et al. Association of LN evaluation with survival in women aged 70 years or older with clinically node-negative hormone receptor positive breast cancer. Ann Surg Oncol. 2017;24(10):3073–81. https://doi.org/10.1245/s10434-017-5936-x .
doi: 10.1245/s10434-017-5936-x
pubmed: 28766195
Laws A, Cheifetz R, Warburton R, et al. Nodal staging affects adjuvant treatment choices in elderly patients with clinically node-negative, estrogen receptor-positive breast cancer. Curr Oncol. 2020;27(5):250–6. https://doi.org/10.3747/co.27.6515 .
doi: 10.3747/co.27.6515
pubmed: 33173376
pmcid: 7606038
Wang T, Baskin A, Miller J, et al. Trends in breast cancer treatment de-implementation in older patients with hormone receptor-positive breast cancer: a mixed methods study. Ann Surg Oncol. 2021;28(2):902–13. https://doi.org/10.1245/s10434-020-08823-w .
doi: 10.1245/s10434-020-08823-w
pubmed: 32651693
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)—Breast Cancer. https://www2.tri-kobe.org/nccn/guideline/breast/english/breast.pdf . Published July 15, 2020. Accessed November 17, 2020.
Giuliano AE, McCall L, Beitsch P, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg. 2010;252(3):426–33. https://doi.org/10.1097/SLA.0b013e3181f08f32 .
doi: 10.1097/SLA.0b013e3181f08f32
pubmed: 20739842
Martelli G, Miceli R, De Palo G, et al. Is axillary lymph node dissection necessary in elderly patients with breast carcinoma who have a clinically uninvolved axilla? Cancer. 2003;97(5):1156–63. https://doi.org/10.1002/cncr.11173 .
doi: 10.1002/cncr.11173
pubmed: 12599220
Martelli G, Miceli R, Daidone MG, et al. Axillary dissection versus no axillary dissection in elderly patients with breast cancer and no palpable axillary nodes: results after 15 years of follow-up. Ann Surg Oncol. 2011;18(1):125–33. https://doi.org/10.1245/s10434-010-1217-7 .
doi: 10.1245/s10434-010-1217-7
pubmed: 20652755
Martelli G, Boracchi P, Ardoino I, et al. Axillary dissection versus no axillary dissection in older patients with T1N0 breast cancer: 15-year results of a randomized controlled trial. Ann Surg. 2012;256(6):920–4. https://doi.org/10.1097/SLA.0b013e31827660a8 .
doi: 10.1097/SLA.0b013e31827660a8
pubmed: 23154393
Aziz D, Gardner S, Pritchard K, Paszat L, Holloway CM. Selective application of axillary node dissection in elderly women with early breast cancer. Ann Surg Oncol. 2007;14(2):652–9. https://doi.org/10.1245/s10434-006-9092-y .
doi: 10.1245/s10434-006-9092-y
pubmed: 17151795
Van Leeuwen BL, Rosenkranz KM, Feng LL, et al. The effect of under-treatment of breast cancer in women 80 years of age and older. Crit Rev Oncol Hematol. 2011;79(3):315–20. https://doi.org/10.1016/j.critrevonc.2010.05.010 .
doi: 10.1016/j.critrevonc.2010.05.010
pubmed: 20655242
Kunkler IH, Williams LJ, Jack WJ, Cameron DA, Dixon JM, PRIME II investigators. Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial [published correction appears in Lancet Oncol. 2015 Mar;16(3):e105]. Lancet Oncol. 2015;16(3):266–273. https://doi.org/10.1016/S1470-2045(14)71221-5
A Prospective Cohort Study Evaluating Risk of Local Recurrence Following Breast Conserving Surgery and Endocrine Therapy in Low Risk Luminal A Breast Cancer (LUMINA). ClinicalTrials.gov identifier: NCT01791829. Updated September 3, 2020. Accessed November 23, 2020. https://clinicaltrials.gov/ct2/show/NCT01791829
Limited Adjuvant Endocrine Therapy for Low Risk Breast Cancer (LALEAST). ClinicalTrials.gov identifier: NCT03917082. Updated December 9, 2020. Accessed January 15, 2021. https://clinicaltrials.gov/ct2/show/NCT03917082?term=Lohrisch&cond=Breast+Cancer&draw=2&rank=1
Hughes KS, Schnaper LA, Bellon JR, et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol. 2013;31(19):2382–7. https://doi.org/10.1200/JCO.2012.45.2615 .
doi: 10.1200/JCO.2012.45.2615
pubmed: 23690420
pmcid: 3691356
Zhong Y, Xu Y, Zhou Y, et al. Omitting radiotherapy is safe in breast cancer patients ≥ 70 years old after breast-conserving surgery without axillary lymph node operation. Sci Rep. 2020;10:19481. https://doi.org/10.1038/s41598-020-76663-5 .
doi: 10.1038/s41598-020-76663-5
pubmed: 33173112
pmcid: 7655830
Nichol AM, Chan EK, Lucas S, et al. The use of hormone therapy alone versus hormone therapy and radiation therapy for breast cancer in elderly women: a population-based study. Int J Radiat Oncol Biol Phys. 2017;98(4):829–39. https://doi.org/10.1016/j.ijrobp.2017.02.094 .
doi: 10.1016/j.ijrobp.2017.02.094
pubmed: 28602413
Taylor LJ, Steiman JS, Anderson B, et al. Does persistent use of radiation in women > 70 years of age with early-stage breast cancer reflect tailored patient-centered care? Breast Cancer Res Treat. 2020;180(3):801–7. https://doi.org/10.1007/s10549-020-05579-5 .
doi: 10.1007/s10549-020-05579-5
pubmed: 32125557
pmcid: 7474974
Wang T, Mott N, Miller J, et al. Patient perspectives on treatment options for older women with hormone receptor-positive breast cancer: a qualitative study. JAMA Netw Open. 2020;3(9):e2017129. https://doi.org/10.1001/jamanetworkopen.2020.17129 .
doi: 10.1001/jamanetworkopen.2020.17129
pubmed: 32960279
pmcid: 7509630